Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated